Some more from Gerald. Thx FG! FG : @G_Commish
Post# of 30028
(Total Views: 475)
Posted On: 12/16/2021 10:24:16 PM
Some more from Gerald.
Thx FG!
FG : @G_Commish why is NLC pharma extending the deadline for deal closure beyond the phase 2 data release? Doesn't seem right
Gerald : We are wrapping legal due diligence, we need to extend. We tried to get it done by 15th, but I said on Conf call it might go past for this reason. No big deal, Todos and NLC are already working under our 2020 agreement. 3CL Sciences is being created as focused entity to take in/1
funding in a way that is non-dilutive to Todos. I did Cutanogen acquisition in summer of 2015 at Amarantus and the way we did it ended up not best outcome heading to uplist. This structure much friendlier to shareholders and maintains near limitless upside if Tollovir hits
https://twitter.com/G_Commish/status/14716602...g&s=19
Q: (To Gerald , do you believe the FDA may possibly give Tollovir EUA even if the number of patients in the phase 2 study is relatively small ? I’m don’t know if there are any requirement in study size that FDA requires)
A: Only time will tell. And the need will also drive. In Europe, they’re telling countries to use even before actually reviewing anything, that’s the level of confidence in 3CLpro inhibitors
Thx FG!
FG : @G_Commish why is NLC pharma extending the deadline for deal closure beyond the phase 2 data release? Doesn't seem right
Gerald : We are wrapping legal due diligence, we need to extend. We tried to get it done by 15th, but I said on Conf call it might go past for this reason. No big deal, Todos and NLC are already working under our 2020 agreement. 3CL Sciences is being created as focused entity to take in/1
funding in a way that is non-dilutive to Todos. I did Cutanogen acquisition in summer of 2015 at Amarantus and the way we did it ended up not best outcome heading to uplist. This structure much friendlier to shareholders and maintains near limitless upside if Tollovir hits
https://twitter.com/G_Commish/status/14716602...g&s=19
Q: (To Gerald , do you believe the FDA may possibly give Tollovir EUA even if the number of patients in the phase 2 study is relatively small ? I’m don’t know if there are any requirement in study size that FDA requires)
A: Only time will tell. And the need will also drive. In Europe, they’re telling countries to use even before actually reviewing anything, that’s the level of confidence in 3CLpro inhibitors
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼